```html

Wegener's Glomerulonephritis

Overview

Wegener's glomerulonephritis is a form of renal involvement in anti‑neutrophil cytoplasmic antibody‑associated vasculitis (AAV), historically called Wegener’s granulomatosis. The disease is characterized by inflammation of small‑to‑medium blood vessels that leads to necrotizing glomerulonephritis—damage to the kidney’s filtering units. It most often occurs as part of Granulomatosis with polyangiitis (GPA) but can appear in microscopic polyangiitis (MPA) or as an isolated renal-limited vasculitis.

• Typical age of onset: 40–60 years, though children and older adults can be affected.
• Gender: Slight male predominance (≈55% male).
• Prevalence: GPA affects ~ 3–10 per 100,000 people worldwide; renal involvement occurs in 60–80 % of cases, making Wegener’s glomerulonephritis relatively rare but clinically significant (Cleveland Clinic, 2020).
• Geography: Similar incidence across North America, Europe, and Asia; no clear ethnic predilection.

Symptoms

Symptoms arise from two sources: systemic vasculitis and kidney dysfunction. Because early disease can be subtle, a high index of suspicion is essential.

Systemic (non‑renal) manifestations

• Upper airway: Nasal crusting, chronic sinusitis, epistaxis, otitis media, or saddle‑nose deformity.
• Lower airway: Cough, hemoptysis, shortness of breath, or pulmonary nodules.
• Skin: Palpable purpura, livedo reticularis, or necrotic ulcers.
• Eyes: Conjunctivitis, scleritis, or peripheral ulcerative keratitis.
• Neurologic: Mononeuritis multiplex, peripheral neuropathy, or cranial nerve palsies.
• General: Fever, weight loss, fatigue, night sweats, and arthralgias.

Renal (glomerulonephritis) manifestations

• Hematuria: Microscopic or gross blood in the urine, often described as “cola‑colored.”
• Proteinuria: Usually sub‑nephrotic (≤3 g/24 h) but can be higher.
• Reduced urine output: Oliguria or anuria in severe cases.
• Edema: Swelling of ankles, feet, or periorbital region due to fluid retention.
• Hypertension: Elevated blood pressure from sodium retention and renin‑angiotensin activation.
• Elevated serum creatinine & BUN: Indicators of declining kidney function.
• Acute kidney injury (AKI): Rapid rise in creatinine over days to weeks.

Causes and Risk Factors

The exact trigger remains unknown, but current evidence points to an autoimmune process driven by anti‑neutrophil cytoplasmic antibodies (ANCAs), most often directed against proteinase‑3 (PR3‑ANCA) in GPA.

Key pathogenic mechanisms

• ANCA‑mediated neutrophil activation: ANCAs bind to neutrophil cytoplasmic antigens, causing degranulation and endothelial injury.
• Genetic predisposition: Certain HLA‑DP and HLA‑DQ alleles increase susceptibility.
• Environmental triggers: Silica exposure, chronic nasal carriage of Staphylococcus aureus, and certain drugs (e.g., propylthiouracil, hydralazine) have been linked to ANCA formation.

Risk factors

• Age 40–60 years
• Male sex (slight increase)
• History of chronic sinus disease or occupational silica exposure
• Use of ANCA‑inducing medications
• Family history of autoimmune disease

Diagnosis

Diagnosing Wegener’s glomerulonephritis requires a combination of clinical evaluation, laboratory testing, imaging, and, crucially, kidney biopsy.

Laboratory tests

• Serum ANCA testing: Positive PR3‑ANCA (c‑ANCA) in ~ 85 % of GPA cases.
• Urinalysis: Hematuria with red‑cell casts, proteinuria.
• Renal function panel: Elevated creatinine, BUN, and reduced eGFR.
• Inflammatory markers: ESR & CRP often markedly elevated.
• Complement levels: Typically normal, helping differentiate from lupus nephritis.

Imaging

• Chest X‑ray / CT: Detects pulmonary nodules, cavitations, or alveolar hemorrhage.
• Sinus CT: Shows mucosal thickening, bony erosion.
• Renal ultrasound: May reveal normal‑size kidneys early; later, increased echogenicity.

Kidney biopsy (gold standard)

Biopsy typically shows a necrotizing, crescentic glomerulonephritis with little or no immune‑complex deposition (“pauci‑immune”). The presence of crescents in ≥50 % of glomeruli predicts rapid progression and guides treatment intensity (Mayo Clinic).

Treatment Options

Therapy aims to induce remission quickly, then maintain it while preserving kidney function. Treatment is individualized based on disease severity (e.g., the Birmingham Vasculitis Activity Score) and organ involvement.

Induction therapy (to achieve remission)

• High‑dose glucocorticoids: Methylprednisolone 500–1000 mg IV daily for 3 days, then oral prednisone 1 mg/kg/day with a taper over 4–6 months.
• Cyclophosphamide: IV pulse (15 mg/kg) every 2–3 weeks or oral (2 mg/kg/day). Preferred for severe renal disease.
• Rituximab: Anti‑CD20 monoclonal antibody (375 mg/m² weekly ×4 or 1 g on days 1 and 15). Equal efficacy to cyclophosphamide for induction, especially in patients desiring fertility preservation (NEJM, 2015).
• Plasma exchange (PLEX): Considered for rapidly progressive glomerulonephritis (creatinine >5 mg/dL or pulmonary hemorrhage). Recent PEXIVAS trial suggests limited mortality benefit but may protect kidneys in select patients.

Maintenance therapy (to prevent relapse)

• Azathioprine: 2 mg/kg/day, or mycophenolate mofetil: 1–1.5 g twice daily.
• Rituximab: 500 mg IV every 6 months for 2–5 years in high‑risk patients.
• Low‑dose glucocorticoids: Prednisone ≤5 mg/day for the first 12–18 months, then taper.

Adjunctive measures

• Vaccinations (influenza, pneumococcal, COVID‑19) before immunosuppression.
• Prophylaxis for opportunistic infections (e.g., TMP‑SMX for Pneumocystis jirovecii).
• Bone health: calcium, vitamin D, and bisphosphonates if on long‑term steroids.

Living with Wegener's Glomerulonephritis

Chronic disease management focuses on medication adherence, monitoring kidney health, and lifestyle choices that reduce cardiovascular risk.

Daily management tips

• Medication schedule: Use a pill organizer, set alarms, and keep a medication list for every appointment.
• Regular labs: CBC, electrolytes, creatinine, eGFR, and ANCA titers every 1–3 months during induction, then every 3–6 months.
• Blood pressure control: Aim for <130/80 mm Hg; ACE inhibitors or ARBs are kidney‑protective.
• Hydration: Adequate fluid intake unless limited by edema or heart failure.
• Diet: Low‑sodium, moderate protein (0.8 g/kg/day), and low‑potassium if hyperkalemia is present.
• Exercise: Moderate activity (30 min, most days) improves cardiovascular health without overtaxing kidneys.
• Stress management: Mindfulness, counseling, or support groups (e.g., Vasculitis Foundation).

Follow‑up care

Regular visits with a nephrologist and rheumatologist are essential. Annual eye exams are recommended if high‑dose steroids are used long term.

Prevention

Because the disease is autoimmune, primary prevention is limited. However, risk reduction strategies include:

• Avoiding known drug triggers (e.g., propylthiouracil, hydralazine) when possible.
• Limiting occupational silica exposure—use protective masks and adequate ventilation.
• Prompt treatment of chronic sinus infections to reduce bacterial colonization.
• Maintaining good vaccination status to lower infection‑driven immune activation.

Complications

If left untreated or poorly controlled, Wegener’s glomerulonephritis can lead to serious outcomes:

• End‑stage renal disease (ESRD): Up to 30 % of patients progress to dialysis or transplantation within 5 years of diagnosis (Kidney International, 2020).
• Hypertensive heart disease: Chronic hypertension accelerates coronary artery disease.
• Pulmonary hemorrhage: Life‑threatening bleeding into the lungs.
• Secondary infections: Due to immunosuppression—bacterial, fungal, or viral (e.g., shingles).
• Osteoporosis & avascular necrosis: From long‑term glucocorticoid use.
• Malignancy: Slightly increased risk of bladder cancer with cyclophosphamide.

When to Seek Emergency Care

References

• Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). https://www.mayoclinic.org/diseases‑conditions/granulomatosis‑with‑polyangiitis
• Cleveland Clinic. Anti‑neutrophil cytoplasmic antibody (ANCA) vasculitis. https://my.clevelandclinic.org/health/diseases/14841-anca-associated-vasculitis
• Stone JH et al. Rituximab versus cyclophosphamide for ANCA‑associated vasculitis. NEJM. 2010;363:221‑32.
• Peck A et al. Outcomes of renal limited vasculitis. Kidney International. 2020;98:467‑476.
• Harambat J, et al. Epidemiology and outcomes of ANCA‑associated glomerulonephritis. Kidney Int Rep. 2021;6:1332‑1343.
• Walsh M, et al. PEXIVAS trial: Plasma exchange in ANCA vasculitis. NEJM. 2020;383:622‑632.
• CDC. Vaccine recommendations for immunocompromised adults. https://www.cdc.gov/vaccines
• WHO. Autoimmune diseases: Global burden and strategies. https://www.who.int

```